Proactive Investors - Run By Investors For Investors

NetScientific PLC 's Wanda sets up scientific advisory board

Wanda has developed a way to monitor digitally people with congestive heart failure and other chronic conditions
NetScientific PLC 's Wanda sets up scientific advisory board
Wanda has attracted a heavyweight panel to advise it

Wanda, one of healthcare tech investor NetScientific plc’s (LON:NSCI) core investments, has formed a scientific advisory board to guide the management  team.

The board will include distinguished physicians, health economics scientists, and technologists committed to advancing clinical outcomes for individuals with chronic disease.

Wanda has developed a way to digitally monitor people with congestive heart failure and other chronic conditions.

Last month, it announced the launch of a software platform to improve cancer care in collaboration with leading US hospital group Dignity Health.

Francois Martelet, NetScientific's chief executive, said: "Wanda's technology has broad potential to simplify and improve the lives of people confronted with chronic conditions and, in the near term, to help patients with congestive heart failure and their physicians to monitor risk and predict and prevent readmission to hospital.  

“The calibre of the new SAB members is testament to the quality of the Wanda platform and we look forward to their input as Wanda develops into a world-leading digital health business."

Members of the new Wanda board include: Constanzo DiPerna, - medical director of Dignity Health Cancer Institute of Greater Sacramento; Clyde Wesp, executive clinical strategist at Jacobus Consulting; Janki Shah, founder and director of the UCLA Northwest Valley Women's Heart Health Program and Jeff Moreland, CEO and chief patient officer for Patient Engagement Advisors (PEA).

Why Invest In Netscientific PLC? Read More Here

Register here to be notified of future NSCI Company articles
View full NSCI profile

Netscientific PLC Timeline

Related Articles

September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
Cancer cell graphic
September 27 2016
Shares in Sareum have rocketed over 150% after it announced its cancer drug candidate has been licensed to ProNAi Therapeutics.
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.